Specify a stock or a cryptocurrency in the search bar to get a summary
Royalty Pharma Plc
RPRXRoyalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York. Address: 110 East 59th Street, New York, NY, United States, 10022
Analytics
WallStreet Target Price
44.83 USDP/E ratio
18.1133Dividend Yield
3.06 %Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures RPRX
Dividend Analytics RPRX
Dividend growth over 5 years
–Continuous growth
3 yearsPayout Ratio 5 years average
279 %Dividend History RPRX
Stock Valuation RPRX
Financials RPRX
Results | 2019 | Dynamics |